<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arch Dermatol Res</journal-id>
      <journal-title>Archives of Dermatological Research</journal-title>
      <issn pub-type="ppub">0340-3696</issn>
      <issn pub-type="epub">1432-069X</issn>
      <publisher>
        <publisher-name>Springer-Verlag</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">17021761</article-id>
      <article-id pub-id-type="pmc">1705513</article-id>
      <article-id pub-id-type="publisher-id">707</article-id>
      <article-id pub-id-type="doi">10.1007/s00403-006-0707-8</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Symposium Proceeding</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Mrowietz</surname>
            <given-names>Ulrich</given-names>
          </name>
          <address>
            <phone>+49-431-5971512</phone>
            <fax>+49-431-5971543</fax>
            <email>umrowietz@dermatology.uni-kiel.de</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Elder</surname>
            <given-names>James T.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Barker</surname>
            <given-names>Jonathan</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Department of Dermatology, University of Kiel, Schittenhelmstr. 7, 24105 Kiel, Germany </aff>
        <aff id="Aff2"><label>2</label>Department of Dermatology and Radiation Oncology, University of Michigan Medical School, 3312 CCGC Box 0932, Ann Arbor, MI 48109 USA </aff>
        <aff id="Aff3"><label>3</label>St. John&#x2019;s Institute of Dermatology, St. Thomas&#x2019; Hospital, Lambeth Palace Rd, London, SE1 7EH UK </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>5</day>
        <month>10</month>
        <year>2006</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>12</month>
        <year>2007</year>
      </pub-date>
      <volume>298</volume>
      <issue>7</issue>
      <fpage>309</fpage>
      <lpage>319</lpage>
      <history>
        <date date-type="received">
          <day>26</day>
          <month>7</month>
          <year>2006</year>
        </date>
        <date date-type="rev-recd">
          <day>31</day>
          <month>8</month>
          <year>2006</year>
        </date>
        <date date-type="accepted">
          <day>4</day>
          <month>9</month>
          <year>2006</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Springer-Verlag 2006</copyright-statement>
      </permissions>
      <abstract>
        <p>It is well established that several inflammatory-type conditions, such as arthritis, diabetes, cardiovascular disease, and irritable bowel disease exist comorbidly and at an increased incidence in patients with psoriasis. Psoriasis and other associated diseases are thought to share common inflammatory pathways. Conditions such as these, with similar pathogenic mechanisms involving cytokine dysregulation, are referred to as immune-mediated inflammatory diseases (IMIDs). Considerable evidence for the genetic basis of cormobidities in psoriasis exists. The WHO has reported that the occurrence of chronic diseases, including IMIDs, are a rising global burden. In addition, conditions linked with psoriasis have been associated with increasing rates of considerable morbidity and mortality. The presence of comorbid conditions in psoriasis patients has important implications for clinical management. QoL, direct health care expenditures and pharmacokinetics of concomitant therapies are impacted by the presence of comorbid conditions. For example, methotrexate is contraindicated in hepatic impairment, while patients on ciclosporin should be monitored for kidney function. In addition, some agents, such as beta blockers, lithium, synthetic antimalarial drugs, NSAIDs and tetracycline antibiotics, have been implicated in the initiation or exacerbation of psoriasis. Consequently, collaboration between physicians in different specialties is essential to ensuring that psoriasis treatment benefits the patient without exacerbating associated conditions.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Psoriasis</kwd>
        <kwd>Comorbid</kwd>
        <kwd>Quality-of-life</kwd>
        <kwd>Biologics</kwd>
        <kwd>Inflammation</kwd>
      </kwd-group>
      <custom-meta-wrap>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer-Verlag 2006</meta-value>
        </custom-meta>
      </custom-meta-wrap>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Psoriasis: from gene to clinic</title>
      <p>A satellite symposium held at the Royal College of Physicians, London, United Kingdom, in December 2005 investigated the associations between psoriasis, comorbid diseases and concomitant therapy and their significance for long-term patient treatment. The programme generated substantial debate and raised some clinically significant issues, which are further outlined here.</p>
    </sec>
    <sec id="Sec2" sec-type="introduction">
      <title>Introduction</title>
      <p>Psoriasis is a common, chronic, immune-mediated inflammatory disease with a recognised genetic predisposition. It has been observed that, while the frequency of skin conditions such as acne, urticaria and atopic dermatitis are reduced in patients with psoriasis compared with expected frequencies in the general population, the frequency of some noncutaneous, although related, conditions is significantly increased [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. Perhaps the best known noncutaneous condition associated with psoriasis is joint disease, mostly expressed as psoriatic arthritis (PsA). In hospitalised psoriasis patients, a diagnosis of PsA [according to the European Spondyloarthropathy Study Group (ESSG) criteria] was present in 7.7% (71/936) of patients; however, many more patients also reported paresthesias (12.3%), arthralgia (7%), stiffness (4.2%), swelling (3.7%) and ankylosis (1.2%) without meeting all of the ESSG criteria for PsA [<xref ref-type="bibr" rid="CR19">19</xref>]. Further estimates place the occurrence of PsA in patients with psoriasis at upwards of 30% [<xref ref-type="bibr" rid="CR31">31</xref>]. An additional study by Zachariae et al. [<xref ref-type="bibr" rid="CR83">83</xref>] established even higher rates for psoriasis with joint involvement in 5,795 members of psoriasis associations from the Nordic countries and 702 patients seen by Nordic dermatologists. The result showed that upwards of 30% of all patients who presented with psoriasis were also diagnosed with arthritis by their dermatologist or a rheumatologist. In a recent study in a geographically defined population in Norway Madland et al. [<xref ref-type="bibr" rid="CR41">41</xref>] found a prevalence of PsA in 2 per 1,000 inhabitants, which corresponds to about 10% in patients with psoriasis assuming a prevalence of psoriasis of 2%.</p>
      <p>These results demonstrate that the prevalence of arthritis in patients with psoriasis may actually be higher than the previously accepted rate of 7% [<xref ref-type="bibr" rid="CR83">83</xref>]. Inflammatory bowel disease is also more frequently observed in patients with psoriasis. An increased relative risk for Crohn&#x2019;s disease (CD) of 2.9 was found to be associated with a prior diagnosis of psoriasis in a Swedish case-control study [<xref ref-type="bibr" rid="CR54">54</xref>]. Conversely, patients with CD are about seven times more likely to develop psoriasis than controls [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR82">82</xref>].</p>
      <p>Analysis of data from more than 40,000 dermatological inpatients with psoriasis compared with control patients with nonpsoriatic skin diseases (adjusting for age and gender) revealed high ratios of observed versus expected frequencies for obesity (2.05, <italic>P&#xA0;</italic>&lt;&#xA0;0.05), hypertension (1.90, <italic>P&#xA0;</italic>&lt;&#xA0;0.01), heart failure (1.83, <italic>P&#xA0;</italic>&lt;&#xA0;0.001) and diabetes mellitus (1.47, <italic>P&#xA0;</italic>&lt;&#xA0;0.05) [<xref ref-type="bibr" rid="CR26">26</xref>]. An additional analysis (retrospective chart review, 1997&#x2013;2000) of 753 patients from an academic dermatology practice also confirms the presence of comorbidities in patients with psoriasis [<xref ref-type="bibr" rid="CR53">53</xref>]. In fact, a comorbid diagnosis was confirmed in 551 patients (73%), with hypertension, dyslipidemia, diabetes and heart disease being the most common comorbidities identified [<xref ref-type="bibr" rid="CR53">53</xref>]. Furthermore, patients with psoriasis appear to be at increased risk of atherosclerosis, which may at least in part be explained by an abnormal plasma lipid metabolism; serum lipoprotein (a) and triglycerides are significantly increased in patients with psoriasis compared with healthy control subjects [<xref ref-type="bibr" rid="CR73">73</xref>], while high-density lipoprotein (HDL) cholesterol is significantly decreased [<xref ref-type="bibr" rid="CR60">60</xref>]. Indeed, in patients with PsA, alterations of the lipid profile suggest similarities to the diabetic lipid profile, which is known to substantially increase cardiovascular risk [<xref ref-type="bibr" rid="CR30">30</xref>].</p>
      <p>Nearly 30&#xA0;years ago it was reported that the rates of occlusive vascular disease were significantly higher in dermatological patients with psoriasis than those without and that the risk was greater in patients with predisposing factors [<xref ref-type="bibr" rid="CR44">44</xref>]. Metabolic syndrome has since been identified as a clustering of metabolic abnormalities in individuals and is associated with a threefold increase in type 2 diabetes and a twofold increase in cardiovascular disease [<xref ref-type="bibr" rid="CR86">86</xref>]. The most recent definition of metabolic syndrome requires central obesity (defined as body mass index &gt;30&#xA0;kg/m<sup>2</sup>) plus any two of the following: elevated plasma triglycerides, reduced HDL cholesterol, elevated blood pressure and raised fasting plasma glucose (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). Such clustering of risk factors has been observed in patients with psoriasis [<xref ref-type="bibr" rid="CR26">26</xref>].
<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>Diseases associated with psoriasis [<xref ref-type="bibr" rid="CR65">65</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Condition</th><th align="left">Prevalence in psoriasis <italic>n</italic> (%)</th><th align="left">Hospital controls <break/>OR (95% CI)</th><th align="left">RKI sample OR (95% CI)</th></tr></thead><tbody><tr><td align="left">Diabetes mellitus type I</td><td align="left">11 (1.9)</td><td align="left">3.99 (1.30&#x2013;12.2)*</td><td align="left">6.34 (2.80&#x2013;14.3)***</td></tr><tr><td align="left">Diabetes mellitus type II</td><td align="left">68 (11.7)</td><td align="left">2.48 (1.70&#x2013;3.61)**</td><td align="left">2.07 (1.50&#x2013;2.85)***</td></tr><tr><td align="left">Arterial hypertension</td><td align="left">127 (21.9)</td><td align="left">3.27 (2.41&#x2013;4.43)***</td><td align="left">1.39 (1.09&#x2013;1.77)*</td></tr><tr><td align="left">Hyperlipoproteinemia</td><td align="left">30 (5.2)</td><td align="left">2.09 (1.23&#x2013;3.54)**</td><td align="left">0.83 (0.54&#x2013;1.28)<sup>f</sup></td></tr><tr><td align="left">Coronary heart disease</td><td align="left">32 (5.5)</td><td align="left">1.77 (1.07&#x2013;2.93)*</td><td align="left">0.93(0.60&#x2013;1.43)<sup>f</sup></td></tr><tr><td align="left">Metabolic syndrome</td><td align="left">25 (4.3)</td><td align="left">5.92 (2.78&#x2013;12.8)***</td><td align="left">2.20 (1.41&#x2013;3.43)**</td></tr><tr><td align="left">Alcohol consumption none vs. moderate</td><td align="left">246 (42.3)</td><td align="left">2.78 (2.14&#x2013;3.62)***</td><td align="left">2.03 (1.62&#x2013;2.55)***</td></tr><tr><td align="left">None vs. regularly</td><td align="left">75 (12.9)</td><td align="left">3.33 (2.20&#x2013;5.05)***</td><td align="left">2.00 (1.45&#x2013;2.77)***</td></tr><tr><td align="left">None vs. heavy<sup>a</sup></td><td align="left">24 (4.1)</td><td align="left">3.61 (1.85&#x2013;7.07)***</td><td align="left">8.50 (5.28&#x2013;16.8)***</td></tr><tr><td align="left">Cigarette smoking</td><td align="left">264 (45.4)</td><td align="left">2.96 (2.27&#x2013;3.84)***</td><td align="left">2.49 (2.00&#x2013;3.10)***</td></tr></tbody></table><table-wrap-foot><p>The prevalence of diseases in plaque-type psoriasis patients (<italic>n</italic>&#xA0;=&#xA0;581) was compared with hospital-based controls (<italic>n</italic>&#xA0;=&#xA0;1,044) and a population-based survey (RKI sample; <italic>n</italic>&#xA0;=&#xA0;4,705). Common odds ratios adjusted for age and sex are presented with their 95% confidence intervals (95% CI), <italic>f</italic>&#xA0;not significant</p><p><sup>a</sup>Due to low numbers, only adjusted for sex</p><p>*<italic>P&#xA0;</italic>&lt;&#xA0;0.05; ** <italic>P&#xA0;</italic>&lt;&#xA0;0.01; ***<italic>P&#xA0;</italic>&lt;&#xA0;0.0001 by Mantel&#x2013;Haenszel test</p></table-wrap-foot></table-wrap></p>
      <p>Psoriasis, especially in patients with more severe disease, has also been associated with other factors that can increase cardiovascular risk, thereby increasing morbidity and mortality. Alcoholism and liver cirrhosis are reportedly more common in psoriasis [<xref ref-type="bibr" rid="CR39">39</xref>] with a reported prevalence of alcoholism of 18% among psoriatic patients compared with 2% in other dermatologic controls [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Cigarette smoking has also been associated with psoriasis. A recent case-control study revealed that the risk of psoriasis was higher in ex-smokers and current smokers than in those who never smoked (odds ratios of 1.9 and 1.7, respectively), and smoking was strongly associated with the occurrence of pustular lesions (odds ratio&#xA0;=&#xA0;5.3 for smokers) [<xref ref-type="bibr" rid="CR48">48</xref>]. In a cross-sectional study, patients with psoriasis that enrolled in the prospective Utah Psoriasis Initiative had a significantly higher prevalence of obesity and smoking than the general population of Utah (<italic>P&#xA0;</italic>&lt;&#xA0;0.001 for both). The prevalence of obese smokers was significantly higher (<italic>P&#xA0;</italic>&lt;&#xA0;0.001) [<xref ref-type="bibr" rid="CR27">27</xref>].</p>
      <p>A number of psychiatric/psychological comorbidities have also been observed in patients with psoriasis [<xref ref-type="bibr" rid="CR22">22</xref>]. An association between psoriasis and stressful life events in the year preceding diagnosis has been reported, suggesting that psychological stress may have a role in the pathogenesis of psoriasis [<xref ref-type="bibr" rid="CR48">48</xref>]. Furthermore, psoriasis-related stress can play a role in the exacerbation of psoriasis, and greater stress reactivity has been associated with onset of psoriasis at an earlier age [<xref ref-type="bibr" rid="CR22">22</xref>]. High depression/anxiety scores, obsessionality and difficulties with verbal expression of emotions (especially anger) have been reported in various cross-sectional surveys [<xref ref-type="bibr" rid="CR22">22</xref>]. Severely affected psoriatic inpatients (&gt;30% body surface area affected) were likely to suffer clinical depression and suicidal ideation (7.2%); however, suicidal ideation was still relatively high (2.5%) in less severely affected outpatients (&lt;30% total body surface area affected) and comparable to the reported prevalence among general medical patients (2.4&#x2013;3.3%) [<xref ref-type="bibr" rid="CR21">21</xref>].</p>
      <p>These identified diseases associated with psoriasis have led clinicians to look at underlying mechanisms that might be involved and start considering how managing comorbid conditions may impact treatment selection and outcome for the psoriasis patient.</p>
    </sec>
    <sec id="Sec3">
      <title>Common inflammatory pathways in psoriasis and associated diseases</title>
      <p>The immune system has been strongly implicated in the pathogenesis of psoriasis that resembles a T cell-mediated, autoimmune, inflammatory disease [<xref ref-type="bibr" rid="CR7">7</xref>]. T cells are found in the dermis and epidermis and are accompanied by increased numbers of dermal dendritic cells, macrophages and mast cells [<xref ref-type="bibr" rid="CR51">51</xref>]. It is thought that a stimulus (such as trauma or infection) triggers a plexus of cellular events by inciting a cascade of cytokines, creating an inflammatory response. Dendritic cells and T cells become activated with the formation of an immunological synapse&#x2014;a multimolecular complex at the T cell-antigen-presenting cell interface that facilitates immune cell interactions. Once activated, dendritic antigen-presenting cells and T cells release cytokines, chemokines and growth factors, which trigger keratinocyte proliferation, altered differentiation and an angiogenic tissue response, giving rise to psoriatic lesions (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>).
<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>Inflammatory pathway in psoriasis [<xref ref-type="bibr" rid="CR50">50</xref>]. Working model for immunopathogenesis of psoriasis. Multiple stages are proposed for trafficking patterns of immunocytes, involving signals in which symptomless skin is converted into a psoriatic plaque. Key inflammatory events include intraepidermal trafficking by CD8+ T cells and neutrophils. Reproduced with permission from J Clin Invest (2004, 113:1664&#x2013;1675). Copyright 2004, The American Society for Clinical Investigation</p></caption><graphic position="anchor" xlink:href="403_2006_707_Fig1_HTML" id="MO1"/></fig></p>
      <p>Other inflammatory diseases, such as rheumatoid arthritis (RA) and CD, are thought to involve similar pathogenetic mechanisms. Recent research has shown that inflammation plays a key role in atherosclerosis [<xref ref-type="bibr" rid="CR24">24</xref>]. A T-cell infiltrate is always present in atherosclerotic lesions, with activated T cells producing a type 1 helper (Th1) response. Psoriasis is up to seven times more common in patients with CD than in controls [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR82">82</xref>] and, as discussed previously, there is often joint involvement in psoriasis. Such extracutaneous manifestations of the disease substantiate that psoriasis is a systemic disease and not just a skin disease [<xref ref-type="bibr" rid="CR14">14</xref>].</p>
      <p>The term immune-mediated inflammatory disease (I.M.I.D.) has been developed to describe conditions, such as psoriasis, CD and RA, with common inflammatory mechanisms described above involving cytokine dysregulation. This term also encompasses type 1 diabetes mellitus, ulcerative colitis, systemic lupus erythematosus, multiple sclerosis, ankylosing spondylitis and uveitis and may further be expanded to include asthma and atherosclerosis [<xref ref-type="bibr" rid="CR79">79</xref>].</p>
      <sec id="Sec4">
        <title>Atherosclerosis and rheumatoid arthritis</title>
        <p>The prevalence of coronary artery atherosclerosis has been found to be increased in patients with chronic inflammatory conditions, such as RA and systemic lupus erythematosus [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Excess mortality due to coronary heart disease in RA patients was first observed in 1953 [<xref ref-type="bibr" rid="CR11">11</xref>]. In a study of 236 RA patients, the age- and sex-adjusted incidence rate ratio of incident cardiovascular events was calculated to be 3.96 [<xref ref-type="bibr" rid="CR16">16</xref>]. After adjusting for cardiovascular risk factors such as age, weight and smoking status, this figure decreased slightly to 3.17, suggesting that there are additional mechanisms responsible for cardiovascular disease in RA. The risk of cardiovascular disease increases with disease severity (eg, number of joints involved) and disease duration [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR75">75</xref>]: severe coronary artery calcification is more likely in patients with established disease (&gt;10&#xA0;years) compared with controls after adjusting for cardiovascular risk factors (odds ratio&#xA0;=&#xA0;3.42, <italic>P&#xA0;</italic>=&#xA0;0.002) [<xref ref-type="bibr" rid="CR10">10</xref>]. However, there is some emerging evidence for increased atherosclerotic disease in early RA [<xref ref-type="bibr" rid="CR32">32</xref>].</p>
        <p>The lipid profile in RA patients is directly affected by the systemic inflammatory response (active inflammation lowers HDL cholesterol, which leads to increased cardiovascular risk) [<xref ref-type="bibr" rid="CR75">75</xref>]. Endothelial dysfunction, which underlies atherosclerotic plaque development, is associated with markers of systemic inflammation, such as C-reactive protein (CRP), soluble adhesion molecules (sICAM-1 and sE-selectin), IL-6 and TNF-alpha (TNF&#x3B1;) [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR78">78</xref>]. Indeed, treatment with the anti-TNF&#x3B1; agent infliximab, which affects expression of all markers described above, has been shown to improve endothelial function in RA patients [<xref ref-type="bibr" rid="CR28">28</xref>].</p>
      </sec>
      <sec id="Sec5">
        <title>Atherosclerosis and psoriasis</title>
        <p>An increase in cardiovascular disease has been observed in psoriasis patients [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR44">44</xref>] and has been shown to be related to disease severity and age of onset [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. An increased incidence of traditional cardiovascular risk factors is frequently reported [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. In psoriatic patients with a history of at least one hospital admission due to psoriasis, there is about a 50% increase in cardiovascular death as compared with the general population [standardised mortality ratio (SMR)&#xA0;=&#xA0;1.52]. In those patients with 3 or more hospital admissions, the SMR increased to 1.82 and in those patients admitted at younger ages (20&#x2013;39&#xA0;years at first admission), the SMR increased to 2.62 [<xref ref-type="bibr" rid="CR42">42</xref>]. However, the SMR was not increased in those treated as outpatients only, indicating a relationship to disease severity. In patients with PsA, an increase in mortality has also been observed (SMR&#xA0;=&#xA0;1.65 in males and 1.59 in females) and the largest single cause of death is myocardial infarction (27.6%) [<xref ref-type="bibr" rid="CR80">80</xref>]. 
<table-wrap id="Taba"><caption><p>&#xA0;</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left">The increased cardiovascular risk in psoriasis may result from</td></tr><tr><td align="left">&#x2022; The increased prevalence of associated risk factors, such as smoking, obesity, hypertension and alcohol misuse.</td></tr><tr><td align="left">&#x2022; The use of dyslipidaemic therapies, such as corticosteroids, acitretin and ciclosporin.</td></tr><tr><td align="left">&#x2022; An associated unfavourable lipid profile (high triglycerides, low HDL).</td></tr><tr><td align="left">&#x2022; Endothelial dysfunction.</td></tr><tr><td align="left">&#x2022; Uncontrolled inflammation. </td></tr><tr><td align="left">&#x2022; Combination of some or all of the above.</td></tr></tbody></table></table-wrap></p>
        <p>Unfortunately, there is a shortage of published studies corrected for traditional risk factors and no published study has formally assessed systemic vasculature inflammation in psoriasis.</p>
        <p>Both psoriasis and atherosclerosis are T cell-mediated inflammatory conditions and a number of similarities exist between their pathogenetic mechanisms. Numerous factors have been shown to be increased in the serum of psoriatic patients including apolipoprotein E (ApoE), vascular endothelial growth factor (VEGF), sICAM-1, IL-8, soluble interleukin2 receptor (sIL-2R) and TNF&#x3B1; [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. sICAM-1 and sIL-2R are soluble T-cell products [<xref ref-type="bibr" rid="CR15">15</xref>]. ApoE plays a central role in lipoprotein metabolism and has been found to be significantly raised in patients with psoriasis, indicating that abnormal metabolism of lipoprotein exists in psoriasis patients [<xref ref-type="bibr" rid="CR81">81</xref>]. Furthermore, the dyslipidaemic profile exhibited in psoriasis has been shown to modify dendritic cell functions in skin [<xref ref-type="bibr" rid="CR1">1</xref>]. The impaired dendritic cell emigration from the skin parallels impeded migratory clearance of monocyte-derived dendritic cell-like cells from atherosclerotic plaques.</p>
        <p>VEGF mediates endothelial cell mitogenesis and enhances vascular permeability [<xref ref-type="bibr" rid="CR4">4</xref>]. In psoriasis, VEGF is thought to promote localised angiogenesis and in severe psoriasis may act on renal vasculature to induce hyperpermeability with consequent proteinuria [<xref ref-type="bibr" rid="CR12">12</xref>]. A role for VEGF has been postulated in the atherosclerotic process as changes in levels of VEGF and its receptors are present in atherosclerosis, and angiogenesis may play a role in plaque development and destabilisation [<xref ref-type="bibr" rid="CR4">4</xref>].</p>
      </sec>
    </sec>
    <sec id="Sec6">
      <title>Genetic basis of comorbidities</title>
      <p>There is considerable evidence for a genetic element in psoriasis. About 30% of individuals with psoriasis have an affected first-degree relative [<xref ref-type="bibr" rid="CR69">69</xref>], and first-degree relatives are at a five to tenfold increased risk for developing psoriasis themselves [<xref ref-type="bibr" rid="CR70">70</xref>]. Concordance rates for psoriasis are three to four times higher in monozygotic twins than dizygotic twins [<xref ref-type="bibr" rid="CR6">6</xref>], and twin and family studies show that 60&#x2013;90% of the variance in psoriasis liability is due to genetic factors. Finally, linkage and association to the major histocompatability complex (MHC) region has been repeatedly demonstrated [<xref ref-type="bibr" rid="CR58">58</xref>]. However, the presence of many different phenotypes means that not all psoriasis is the same and polygenic inheritance is likely.</p>
      <p>Interestingly, by analysing gene polymorphisms of the receptor of advanced glycation end products (RAGE) in patients with plaque-psoriasis seems to be linked to a genetic risk for cardiovascular disorders in psoriasis patients [<xref ref-type="bibr" rid="CR76">76</xref>].</p>
      <p>A combination of disease-specific and inflammatory modifying genes interacting with the environment likely determines the risk of comorbidity. A major susceptibility gene (Psoriasis Susceptibility 1 or PSORS1) is located in the MHC class I region and maps to an approximately 300-kb interval containing HLA-C and 10 other genes in strong linkage disequilibrium with it [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]. Very recently, through a combination of genomic sequencing and haplotype analysis, HLA-Cw6 itself has been identified as the major disease allele at PSORS1 [<xref ref-type="bibr" rid="CR47">47</xref>].</p>
      <p>The observation that bacterial infections are significantly less common in psoriasis patients with an age of onset &#x2264;40&#xA0;years while immunological skin disorders (allergic contact dermatitis, urticaria and atopic dermatitis) are reduced regardless of age of onset suggests a genetic link between resistance to infection and early-onset psoriasis [<xref ref-type="bibr" rid="CR26">26</xref>].</p>
      <p>Chronic tonsillitis has been observed over three times more frequently than would be expected in patients with psoriasis [<xref ref-type="bibr" rid="CR26">26</xref>]. Interestingly, psoriasis is not associated with other forms of streptococcal infection, suggesting a specific role for the tonsils [<xref ref-type="bibr" rid="CR20">20</xref>]. Recently, identical T-cell receptor rearrangements have been found in the tonsils and lesional skin of psoriatic patients [<xref ref-type="bibr" rid="CR17">17</xref>]. The prevalence of streptococcal infection during sore throat was 10 times higher in people with psoriasis than in controls and can exacerbate chronic plaque psoriasis [<xref ref-type="bibr" rid="CR20">20</xref>]. There was, however, no difference in asymptomatic carriage between psoriasis patients and controls [<xref ref-type="bibr" rid="CR20">20</xref>]. These results suggest either that psoriatic patients are more susceptible to streptococcal infection or that they respond more vigorously to it and are more likely to develop symptoms.</p>
      <p>This apparently defective response to streptococci combined with resistance to a variety of skin infections in psoriasis patients provides an interesting paradox. It is known that streptococcal (and other) infections may initiate psoriasis in genetically predisposed individuals, and psoriasis is characterised by strong Th1 immune deviation. Once the psoriatic cascade has been initiated, increased skin and/or systemic inflammation directed by Th1 cells may be responsible for a lower risk of other infections. Interestingly, bacterial infection (principally with <italic>Chlamydia pneumoniae</italic>) has also been implicated in the pathogenesis of atherosclerosis [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. A phenomenon similar to that seen in psoriasis could contribute to increased risk of cardiovascular disease.</p>
    </sec>
    <sec id="Sec7">
      <title>Clinical importance of comorbidities in psoriasis</title>
      <p>According to the World Health Organization (WHO), the occurrence of chronic disease is a rising global burden. In 2005, all chronic diseases accounted for 72% of the total global burden of disease in the population aged 30 years and older (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>) [<xref ref-type="bibr" rid="CR68">68</xref>]. More than 80% of the burden of chronic diseases occurs in people under age 70&#xA0;years. While psoriasis causes significant morbidity, it is not generally associated with mortality; however, conditions linked with psoriasis are associated with excess mortality [<xref ref-type="bibr" rid="CR56">56</xref>]. For example, the higher prevalence of smoking in the psoriatic population may explain why psoriasis has been associated with lung cancer in middle-aged women [<xref ref-type="bibr" rid="CR39">39</xref>]. A registry of 5,687 patients admitted to the hospital for psoriasis between 1973 and 1984 who were followed for up to 22&#xA0;years until 1995 found a significantly increased mortality for both alcohol- and smoking-related causes [<xref ref-type="bibr" rid="CR56">56</xref>].
<fig id="Fig2"><label>Fig.&#xA0;2</label><caption><p>WHO projected major causes of death 2005 [<xref ref-type="bibr" rid="CR67">67</xref>]. The occurrence of chronic disease is a rising global burden and accounted for 72% of the total global burden of disease in the population aged 30 years and older in 2005. Reproduced with permission from Lancet (2005, 366:1578&#x2013;1582). Copyright 2005, Elsevier Ltd</p></caption><graphic position="anchor" xlink:href="403_2006_707_Fig2_HTML" id="MO2"/></fig></p>
      <p>An increased rate of cardiovascular events has been observed in patients with psoriasis [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR44">44</xref>], and it appears to be related to the severity of disease and age of onset [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. Worldwide, cardiovascular disease is estimated to be the cause of 30% of all deaths in 2005 making it the leading single cause of death worldwide [<xref ref-type="bibr" rid="CR68">68</xref>]. Identification and treatment of modifiable risk factors in patients with psoriasis could result in a lower associated cardiovascular morbidity and mortality [<xref ref-type="bibr" rid="CR55">55</xref>]. Conceptually, the effective systemic control of inflammation in psoriasis could also lead to improvements in comorbid conditions driven by inflammation.</p>
    </sec>
    <sec id="Sec8">
      <title>Implications of comorbidities</title>
      <p>The presence of comorbid conditions in psoriasis patients can have some important implications for clinical management. The general health status of the patient will be affected by all of these associated diseases, with substantial impact on quality of life (QoL) [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR74">74</xref>]. The precise impact of comorbid conditions on QoL in psoriasis patients has not been quantified; however, it is known that the presence of joint involvement can significantly reduce health-related QoL [<xref ref-type="bibr" rid="CR40">40</xref>] and that arthritis and arthralgia are important related factors affecting QoL in patients with psoriasis [<xref ref-type="bibr" rid="CR83">83</xref>]. In fact, the effects of psoriasis on QoL are comparable to the effects observed from other major chronic diseases [<xref ref-type="bibr" rid="CR59">59</xref>]. The authors performed an analysis of 317 patients with psoriasis and found that these patients reported a reduction in physical and mental functioning comparable to that observed in patients with cancer, arthritis, hypertension, heart disease and depression [<xref ref-type="bibr" rid="CR59">59</xref>].</p>
      <p>A US study looking at the direct health care expenditures associated with psoriasis found that psoriasis patients treated with systemic therapy or phototherapy have significantly more comorbidities and higher mean total health care expenditures compared with non-psoriasis patients. Furthermore, selected comorbidities lead to significantly higher mean total health care expenditures in those patients with psoriasis than in those with the same condition without psoriasis [<xref ref-type="bibr" rid="CR13">13</xref>].</p>
      <p>Many of the conditions associated with psoriasis could affect the way drugs are absorbed and eliminated from the body. For example, alcoholism impairs liver function, obesity affects drug distribution in the body, diabetes can impair kidney function, inflammatory bowel disease can reduce absorption from the gastrointestinal tract and smoking can impact the efficacy of some drugs [<xref ref-type="bibr" rid="CR85">85</xref>]. Of course, the presence of these conditions will also lead to increased polypharmacy, increasing the likelihood of drug interactions and making it harder to implement an &#x2018;ideal&#x2019; psoriasis treatment in individuals [<xref ref-type="bibr" rid="CR34">34</xref>].</p>
      <p>The implications of managing a patient with comorbid conditions are<list list-type="bullet"><list-item><p>Focus on inflammation control.</p></list-item><list-item><p>Consider impact on patient as a whole.</p></list-item><list-item><p>Monitor all associated diseases.</p></list-item></list></p>
    </sec>
    <sec id="Sec9">
      <title>Drug interactions in psoriasis</title>
      <p>It has been suggested that some drugs may trigger or exacerbate psoriasis. The most commonly proposed causative agents are beta blockers, lithium, synthetic antimalarial drugs, nonsteroidal anti-inflammatory drugs (NSAIDs) and tetracycline antibiotics [<xref ref-type="bibr" rid="CR72">72</xref>]. Analysis of co-medication according to patients&#x2019; files in 1203 consecutive inpatients hospitalised for treatment of severe psoriasis was conducted between 2003 and 2005 in 9 dermatology departments in Germany [<xref ref-type="bibr" rid="CR84">84</xref>]. The mean age of patients was 50 years (55.9% female, 44.1% male). The mean Psoriasis Area and Severity Index was 26.0, average body mass index was 27.5 and mean age of first manifestation was 33.5&#xA0;years. About one third of patients were found to be taking no systemic medication (34.4%), and 42.4% were taking three or fewer systemic agents. However, nearly a quarter (23.2%) were taking more than three systemic medications and of these, 11.1% were taking more than ten medications (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>). Therefore, physicians caring for patients with psoriasis may consider withdrawal of agents that potentially exacerbate this condition. Further analysis suggests that comorbid cardiac and metabolic disorders are common in these patients: hypertension, 28.8%; type 2 diabetes, 10.5%; dyslipidaemia, 12.5%; hyperuricaemia, 5.3%; arrhythmias, 5.1%; coronary artery disease, 3.2%; and cardiac insufficiency, 2.1%. The presence of renal insufficiency (2.7%) and liver cirrhosis (2.4%) were also noteworthy.
<table-wrap id="Tab2"><label>Table&#xA0;2</label><caption><p>Percentage of psoriasis patients receiving medications for comorbid disease [<xref ref-type="bibr" rid="CR84">84</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Drug class</th><th align="left">Patients (%) (<italic>n</italic>&#xA0;=&#xA0;1,203)</th></tr></thead><tbody><tr><td align="left">ACE inhibitors</td><td align="left">12.3</td></tr><tr><td align="left">Oral anticoagulants</td><td align="left">11.3</td></tr><tr><td align="left">Diuretics</td><td align="left">12.4</td></tr><tr><td align="left">Thyroid drugs</td><td align="left">9.9</td></tr><tr><td align="left">Beta blockers</td><td align="left">7.9</td></tr><tr><td align="left">Psycholeptics</td><td align="left">5.6</td></tr><tr><td align="left">NSAIDs</td><td align="left">7.0</td></tr><tr><td align="left">Lithium salts</td><td align="left">0.70</td></tr><tr><td align="left">Interferon-alpha</td><td align="left">0.25</td></tr></tbody></table></table-wrap></p>
      <sec id="Sec10">
        <title>Risk of interactions with psoriasis therapies</title>
        <p>There is a high risk of drug interactions with both ciclosporin and methotrexate, while retinoids and leflunomide exhibit a lower risk of drug&#x2013;drug interactions. Conversely, treatments with biologics, such as TNF&#x3B1; inhibitors, and fumaric acid esters have no known risk of interactions. A number of medications can cause photosensitivity, which is an issue for any UV treatment of psoriasis (e.g., tetracyclines [doxycyclin] and thiazide diuretics) [<xref ref-type="bibr" rid="CR67">67</xref>].</p>
      </sec>
    </sec>
    <sec id="Sec11">
      <title>Effect of psoriasis treatment on comorbidities</title>
      <p>The importance of considering the impact of treatment of diseases associated with psoriasis cannot be stressed enough. Working with physicians in different specialties (e.g., rheumatology, gastroenterology and cardiology) would allow physicians an opportunity to ensure that the psoriatic treatments do not worsen the associated condition and where possible provide additional benefits.</p>
      <sec id="Sec12">
        <title>Benefits of psoriasis therapy on comorbid conditions</title>
        <p>Since many comorbid conditions have inflammatory mechanisms in common with psoriasis, drugs targeting inflammation and/or suppressing the immune response are often effective in treating both psoriasis and related comorbidities. A number of treatments have shown some efficacy in treating both psoriasis and PsA including methotrexate, ciclosporin, leflunomide, etanercept and infliximab [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. The TNF&#x3B1; inhibitors etanercept and infliximab have demonstrated halting of joint degradation [<xref ref-type="bibr" rid="CR45">45</xref>].</p>
        <sec id="Sec13">
          <title>Crohn&#x2019;s disease</title>
          <p>There are few treatments that are effective in both psoriasis and CD. Azathioprine and 6-mercaptopurine are often used in CD, and they have also shown some efficacy in PsA in small, uncontrolled trials; however, toxicity is likely to restrict their use [<xref ref-type="bibr" rid="CR50">50</xref>]. Low-dose methotrexate has shown some efficacy in CD patients resistant to other therapies; however, its usefulness in the long term has yet to be established [<xref ref-type="bibr" rid="CR66">66</xref>]. Infliximab has been shown to be effective in both attaining and maintaining remission in CD patients [<xref ref-type="bibr" rid="CR23">23</xref>] as well as in the treatment of extra-intestinal cutaneous manifestations [<xref ref-type="bibr" rid="CR61">61</xref>]. Conversely, etanercept has not been shown to be effective in the treatment of CD and may even worsen the condition [<xref ref-type="bibr" rid="CR52">52</xref>]. The difference between the effects of TNF&#x3B1; inhibitors on inflammation in CD are thought to be due in part to their different mechanisms of binding TNF&#x3B1;. Infliximab has higher affinity than etanercept, binding more forms of TNF&#x3B1;, and may induce cell apoptosis [<xref ref-type="bibr" rid="CR35">35</xref>].</p>
        </sec>
        <sec id="Sec14">
          <title>Cardiovascular disease</title>
          <p>Evidence for the improvement of psoriasis-associated cardiovascular risk following psoriasis treatment is limited to a trial of methotrexate in patients with psoriasis or RA [<xref ref-type="bibr" rid="CR57">57</xref>]. Patients prescribed methotrexate had a significantly reduced risk of vascular disease compared with those who did not receive methotrexate (psoriasis, relative risk [RR]&#xA0;=&#xA0;0.73; RA, RR&#xA0;=&#xA0;0.83). Furthermore, risk reduction was greater in those who received a low cumulative dose of methotrexate (psoriasis, RR&#xA0;=&#xA0;0.50; RA, RR&#xA0;=&#xA0;0.65) and in those patients also receiving concomitant folic acid (psoriasis, RR&#xA0;=&#xA0;0.56; RA, RR&#xA0;=&#xA0;0.77). Further work in RA has suggested that anti-TNF&#x3B1; therapy may provide some cardiovascular protection [<xref ref-type="bibr" rid="CR29">29</xref>]. A comparison of two cohorts, one receiving TNF&#x3B1; inhibitors and one receiving standard therapy (derived from patient registries), revealed a reduced age&#x2013;sex adjusted incidence rate of first cardiovascular event in those receiving TNF&#x3B1; inhibitors compared with controls (14.0/1,000 person&#x2013;years at risk vs. 35.4/1,000 person&#x2013;years). After controlling for disability, the age&#x2013;sex adjusted rate ratio was 0.46 (<italic>P&#xA0;</italic>=&#xA0;0.013) in the anti-TNF&#x3B1;-treated cohort versus the not-treated cohort.</p>
          <p>Statins are used to lower lipids in people at risk for cardiovascular events and have been shown to reduce cardiovascular morbidity and mortality; however, statins have also been shown to have anti-inflammatory properties [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. Statins down-regulate the expression of adhesion molecules and the expression of Th1 chemokine receptors on T cells, as well as block the expression of TNF&#x3B1; and interferon-gamma in macrophages among other immunomodulatory actions [<xref ref-type="bibr" rid="CR49">49</xref>]. A double-blind, placebo-controlled trial in 116 patients with RA demonstrated that 40 mg atorvastatin daily, in addition to existing RA therapy, produced a significant reduction in disease activity (<italic>P&#xA0;</italic>=&#xA0;0.004), a significant reduction in inflammatory markers (CRP 50%, <italic>P&#xA0;</italic>&lt;&#xA0;0.0001; ESR 28%, <italic>P&#xA0;</italic>=&#xA0;0.005) and a significant reduction in swollen joint count (&#x2212;2.69 vs &#x2212;0.53; <italic>P&#xA0;</italic>=&#xA0;0.0058) compared with placebo [<xref ref-type="bibr" rid="CR43">43</xref>]. In addition, simvastatin treatment has been shown to significantly reduce serum CRP and TNF&#x3B1; in patients with RA and improve endothelial function [<xref ref-type="bibr" rid="CR71">71</xref>]. Therefore, it has been suggested that statins may have beneficial effects in inflammatory dermatological conditions including psoriasis, and the results of controlled trials are awaited [<xref ref-type="bibr" rid="CR49">49</xref>].</p>
        </sec>
      </sec>
      <sec id="Sec15">
        <title>Potential drawbacks of psoriasis therapy on comorbid conditions</title>
        <p>Other common comorbidities could influence the choice of psoriasis therapies available to the dermatologist. Ciclosporin can induce hyperglycaemia and acitretin can alter glucose tolerance; therefore, they are best avoided in diabetic patients. Methotrexate has been reported to precipitate diabetes and increase insulin requirements due to increased disease progression [<xref ref-type="bibr" rid="CR8">8</xref>]. Ciclosporin is contraindicated in patients with uncontrolled hypertension and acitretin is contraindicated in hyperlipidaemia. Methotrexate and acitretin are contraindicated in the presence of hepatic impairment, which may result from psoriasis-associated alcohol misuse, while ciclosporin may need dosage adjustment and regular monitoring of kidney function since renal dysfunction is a known side effect [<xref ref-type="bibr" rid="CR8">8</xref>].</p>
        <sec id="Sec16">
          <title>Drug interactions and precipitating disease in psoriasis</title>
          <p>A diagnosis of psoriasis also has implications regarding treatment for physicians from specialities other than dermatology. The potential of some drugs (eg, angiotensin-converting enzyme inhibitors, beta blockers, NSAIDs) to &#x2018;trigger&#x2019; psoriasis means that these drugs should be avoided where possible and awareness of this potential should be raised. The potential for drug interactions with some psoriasis drugs is high and this should also be considered when designing therapeutic regimens. Furthermore, the increased risk of cardiovascular events associated with psoriasis should be considered when conducting global cardiovascular risk assessments. If possible, lower cut-off points for treatment should be used in psoriasis patients in an effort to take into consideration their overall cardiovascular risk.</p>
        </sec>
      </sec>
    </sec>
    <sec id="Sec17">
      <title>Discussion and conclusions</title>
      <p>Psoriasis is a multifaceted systemic condition that is not restricted to cutaneous symptoms. There is a need for further research to fully understand the reasons for comorbidities and their implications on treatment and management of psoriasis patients. Data are required to fully characterise risk of cardiovascular disease in psoriasis patients and whether treatment can impact this level of risk. Could effective (systemic) treatment of psoriasis reduce the risk of comorbidities or, conversely, could effective treatment of comorbidities improve psoriasis? Investigation of the genetics of psoriasis and related inflammatory conditions may provide insight into their pathogenesis and points of commonality, which could reveal novel drug targets</p>
      <p>However, while research is conducted, there is a pressing need for education about comorbidities in psoriasis. Dermatologists need to be aware of the likelihood of comorbid conditions to ensure their detection and that psoriasis is managed with consideration of the possible impact on associated comorbid inflammatory conditions. Similarly, physicians from other specialities should be aware of the potential impact of their management strategies on psoriasis and take care not to exacerbate psoriasis when treating associated conditions. A focus on rapid and profound systemic control of inflammation in psoriasis may have added benefits by controlling inflammation associated with comorbid conditions. It is clear that TNF&#x3B1; is a central mediator in psoriasis and many of the recognised associated diseases. Knowledge and awareness of the common inflammatory processes involved should provide the opportunity to more effectively treat the common causes of inflammatory conditions benefitting both physicians and patients. Managing the psoriasis patient as a whole with integrated therapy is likely to maximise outcomes.</p>
    </sec>
  </body>
  <back>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Angeli</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Llodra</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rong</surname>
              <given-names>JX</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization</article-title>
          <source>Immunity</source>
          <year>2004</year>
          <volume>21</volume>
          <fpage>561</fpage>
          <lpage>574</lpage>
          <pub-id pub-id-type="doi">10.1016/j.immuni.2004.09.003</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Angeli V, Llodra J, Rong JX et al (2004) Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity 21:561&#x2013;574 <pub-id pub-id-type="pmid">15485633</pub-id></citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Antoni</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Kavanaugh</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kirkham</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)</article-title>
          <source>Arthritis Rheum</source>
          <year>2005</year>
          <volume>52</volume>
          <fpage>1227</fpage>
          <lpage>1236</lpage>
          <pub-id pub-id-type="doi">10.1002/art.20967</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Antoni CE, Kavanaugh A, Kirkham B et al (2005) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52:1227&#x2013;1236 <pub-id pub-id-type="pmid">15818699</pub-id></citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Asanuma</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Oeser</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Shintani</surname>
              <given-names>AK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Premature coronary-artery atherosclerosis in systemic lupus erythematosus</article-title>
          <source>N Engl J Med</source>
          <year>2003</year>
          <volume>349</volume>
          <fpage>2407</fpage>
          <lpage>2415</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa035611</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Asanuma Y, Oeser A, Shintani AK et al (2003) Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 349:2407&#x2013;2415 <pub-id pub-id-type="pmid">14681506</pub-id></citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Belgore</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Blann</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Neil</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Localisation of members of the vascular endothelial growth factor (VEGF) family and their receptors in human atherosclerotic arteries</article-title>
          <source>J Clin Pathol</source>
          <year>2004</year>
          <volume>57</volume>
          <fpage>266</fpage>
          <lpage>272</lpage>
          <pub-id pub-id-type="doi">10.1136/jcp.2003.012419</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Belgore F, Blann A, Neil D et al (2004) Localisation of members of the vascular endothelial growth factor (VEGF) family and their receptors in human atherosclerotic arteries. J Clin Pathol 57:266&#x2013;272 <pub-id pub-id-type="pmid">14990597</pub-id></citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bernstein</surname>
              <given-names>CN</given-names>
            </name>
            <name>
              <surname>Wajda</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Blanchard</surname>
              <given-names>JF</given-names>
            </name>
          </person-group>
          <article-title>The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study</article-title>
          <source>Gastroenterology</source>
          <year>2005</year>
          <volume>129</volume>
          <fpage>827</fpage>
          <lpage>836</lpage>
          <pub-id pub-id-type="doi">10.1053/j.gastro.2005.06.021</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Bernstein CN, Wajda A, Blanchard JF (2005) The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 129:827&#x2013;836 <pub-id pub-id-type="pmid">16143122</pub-id></citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bhalerao</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bowcock</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
          <article-title>The genetics of psoriasis: a complex disorder of the skin and immune system</article-title>
          <source>Hum Mol Genet</source>
          <year>1998</year>
          <volume>7</volume>
          <fpage>1537</fpage>
          <lpage>1545</lpage>
          <pub-id pub-id-type="doi">10.1093/hmg/7.10.1537</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Bhalerao J, Bowcock AM (1998) The genetics of psoriasis: a complex disorder of the skin and immune system. Hum Mol Genet 7:1537&#x2013;1545 <pub-id pub-id-type="pmid">9735374</pub-id></citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bowcock</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Krueger</surname>
              <given-names>JG</given-names>
            </name>
          </person-group>
          <article-title>Getting under the skin: the immunogenetics of psoriasis</article-title>
          <source>Nat Rev Immunol</source>
          <year>2005</year>
          <volume>5</volume>
          <fpage>699</fpage>
          <lpage>711</lpage>
          <pub-id pub-id-type="doi">10.1038/nri1689</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Bowcock AM, Krueger JG (2005) Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 5:699&#x2013;711 <pub-id pub-id-type="pmid">16138103</pub-id></citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Buckingham</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Sandborg</surname>
              <given-names>CI</given-names>
            </name>
          </person-group>
          <article-title>A randomized trial of methotrexate in newly diagnosed patients with type 1 diabetes mellitus</article-title>
          <source>Clin Immunol</source>
          <year>2000</year>
          <volume>96</volume>
          <fpage>86</fpage>
          <lpage>90</lpage>
          <pub-id pub-id-type="doi">10.1006/clim.2000.4882</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Buckingham BA, Sandborg CI (2000) A randomized trial of methotrexate in newly diagnosed patients with type 1 diabetes mellitus. Clin Immunol 96:86&#x2013;90 <pub-id pub-id-type="pmid">10900154</pub-id></citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Campalani</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Allen</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Fairhurst</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin</article-title>
          <source>Br J Dermatol</source>
          <year>2006</year>
          <volume>154</volume>
          <fpage>345</fpage>
          <lpage>352</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2133.2005.06950.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Campalani E, Allen MH, Fairhurst D et al (2006) Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol 154:345&#x2013;352 <pub-id pub-id-type="pmid">16433808</pub-id></citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chung</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Oeser</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Raggi</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors</article-title>
          <source>Arthritis Rheum</source>
          <year>2005</year>
          <volume>52</volume>
          <fpage>3045</fpage>
          <lpage>3053</lpage>
          <pub-id pub-id-type="doi">10.1002/art.21288</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Chung CP, Oeser A, Raggi P et al (2005) Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 52:3045&#x2013;3053 <pub-id pub-id-type="pmid">16200609</pub-id></citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cobb</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bauer</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Length of life and cause of death in rheumatoid arthritis</article-title>
          <source>N Engl J Med</source>
          <year>1953</year>
          <volume>249</volume>
          <fpage>553</fpage>
          <lpage>556</lpage>
        </citation>
        <citation citation-type="display-unstructured">Cobb S, Anderson F, Bauer W (1953) Length of life and cause of death in rheumatoid arthritis. N Engl J Med 249:553&#x2013;556 <pub-id pub-id-type="pmid">13087647</pub-id></citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Creamer</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Allen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jaggar</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor</article-title>
          <source>Arch Dermatol</source>
          <year>2002</year>
          <volume>138</volume>
          <fpage>791</fpage>
          <lpage>796</lpage>
          <pub-id pub-id-type="doi">10.1001/archderm.138.6.791</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Creamer D, Allen M, Jaggar R et al (2002) Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. Arch Dermatol 138:791&#x2013;796 <pub-id pub-id-type="pmid">12056961</pub-id></citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Crown</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Bresnahan</surname>
              <given-names>BW</given-names>
            </name>
            <name>
              <surname>Orsini</surname>
              <given-names>LS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US</article-title>
          <source>Curr Med Res Opin</source>
          <year>2004</year>
          <volume>20</volume>
          <fpage>1929</fpage>
          <lpage>1936</lpage>
          <pub-id pub-id-type="doi">10.1185/030079904X15192</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Crown WH, Bresnahan BW, Orsini LS et al (2004) The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Curr Med Res Opin 20:1929&#x2013;1936 <pub-id pub-id-type="pmid">15701211</pub-id></citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pita</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Ruffelli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cadoni</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Psoriasis: comparison of immunological markers in patients with acute and remission phase</article-title>
          <source>J Dermatol Sci</source>
          <year>1996</year>
          <volume>13</volume>
          <fpage>118</fpage>
          <lpage>124</lpage>
          <pub-id pub-id-type="doi">10.1016/S0923-1811(96)00517-8</pub-id>
        </citation>
        <citation citation-type="display-unstructured">De Pita O, Ruffelli M, Cadoni S et al (1996) Psoriasis: comparison of immunological markers in patients with acute and remission phase. J Dermatol Sci 13:118&#x2013;124 <pub-id pub-id-type="pmid">8953411</pub-id></citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rie</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Zonneveld</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>Witkamp</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: a comparison of sIL-2R, sCD27, sCD4, sCD8 and sICAM-1</article-title>
          <source>Acta Derm Venereol</source>
          <year>1996</year>
          <volume>76</volume>
          <fpage>357</fpage>
          <lpage>360</lpage>
        </citation>
        <citation citation-type="display-unstructured">De Rie MA, Zonneveld IM, Witkamp L et al (1996) Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: a comparison of sIL-2R, sCD27, sCD4, sCD8 and sICAM-1. Acta Derm Venereol 76:357&#x2013;360 <pub-id pub-id-type="pmid">8891007</pub-id></citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rincon</surname>
              <given-names>ID</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Stern</surname>
              <given-names>MP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors</article-title>
          <source>Arthritis Rheum</source>
          <year>2001</year>
          <volume>44</volume>
          <fpage>2737</fpage>
          <lpage>2745</lpage>
          <pub-id pub-id-type="doi">10.1002/1529-0131(200112)44:12&lt;2737::AID-ART460&gt;3.0.CO;2-#</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Del Rincon ID, Williams K, Stern MP et al (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44:2737&#x2013;2745 <pub-id pub-id-type="pmid">11762933</pub-id></citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Diluvio</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Vollmer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Besgen</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Identical TCR beta-chain rearrangements in streptococcal angina and skin lesions of patients with psoriasis vulgaris</article-title>
          <source>J Immunol</source>
          <year>2006</year>
          <volume>176</volume>
          <fpage>7104</fpage>
          <lpage>7111</lpage>
        </citation>
        <citation citation-type="display-unstructured">Diluvio L, Vollmer S, Besgen P et al (2006) Identical TCR beta-chain rearrangements in streptococcal angina and skin lesions of patients with psoriasis vulgaris. J Immunol 176:7104&#x2013;7111 <pub-id pub-id-type="pmid">16709873</pub-id></citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fraser</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Kuijk</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Westhovens</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis</article-title>
          <source>Ann Rheum Dis</source>
          <year>2005</year>
          <volume>64</volume>
          <fpage>859</fpage>
          <lpage>864</lpage>
          <pub-id pub-id-type="doi">10.1136/ard.2004.024463</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Fraser AD, van Kuijk AW, Westhovens R et al (2005) A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 64:859&#x2013;864 <pub-id pub-id-type="pmid">15528283</pub-id></citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gisondi</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Girolomoni</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sampogna</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis</article-title>
          <source>Eur J Dermatol</source>
          <year>2005</year>
          <volume>15</volume>
          <fpage>279</fpage>
          <lpage>283</lpage>
        </citation>
        <citation citation-type="display-unstructured">Gisondi P, Girolomoni G, Sampogna F et al (2005) Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. Eur J Dermatol 15:279&#x2013;283 <pub-id pub-id-type="pmid">16048759</pub-id></citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gudjonsson</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Thorarinsson</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Sigurgeirsson</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study</article-title>
          <source>Br J Dermatol</source>
          <year>2003</year>
          <volume>149</volume>
          <fpage>530</fpage>
          <lpage>534</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2133.2003.05552.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Gudjonsson JE, Thorarinsson AM, Sigurgeirsson B et al (2003) Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study. Br J Dermatol 149:530&#x2013;534 <pub-id pub-id-type="pmid">14510985</pub-id></citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gupta</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Gupta</surname>
              <given-names>AK</given-names>
            </name>
          </person-group>
          <article-title>Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis</article-title>
          <source>Br J Dermatol</source>
          <year>1998</year>
          <volume>139</volume>
          <fpage>846</fpage>
          <lpage>850</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2133.1998.02511.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Gupta MA, Gupta AK (1998) Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 139:846&#x2013;850 <pub-id pub-id-type="pmid">9892952</pub-id></citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gupta</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Gupta</surname>
              <given-names>AK</given-names>
            </name>
          </person-group>
          <article-title>Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management</article-title>
          <source>Am J Clin Dermatol</source>
          <year>2003</year>
          <volume>4</volume>
          <fpage>833</fpage>
          <lpage>842</lpage>
          <pub-id pub-id-type="doi">10.2165/00128071-200304120-00003</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Gupta MA, Gupta AK (2003) Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol 4:833&#x2013;842 <pub-id pub-id-type="pmid">14640776</pub-id></citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hanauer</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Feagan</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Lichenstein</surname>
              <given-names>GR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Maintenance infliximab for Crohn&#x2019;s disease: the ACCENT I randomised trial</article-title>
          <source>Lancet</source>
          <year>2002</year>
          <volume>359</volume>
          <fpage>1541</fpage>
          <lpage>1549</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(02)08512-4</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Hanauer SB, Feagan BG, Lichenstein GR et al (2002) Maintenance infliximab for Crohn&#x2019;s disease: the ACCENT I randomised trial. Lancet 359:1541&#x2013;1549 <pub-id pub-id-type="pmid">12047962</pub-id></citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hansson</surname>
              <given-names>GK</given-names>
            </name>
          </person-group>
          <article-title>Inflammation, atherosclerosis and coronary artery disease</article-title>
          <source>N Engl J Med</source>
          <year>2005</year>
          <volume>352</volume>
          <fpage>1685</fpage>
          <lpage>1695</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMra043430</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Hansson GK (2005) Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 352:1685&#x2013;1695 <pub-id pub-id-type="pmid">15843671</pub-id></citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Helms</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Saccone</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Localization of PSORS1 to a haplotype block harbouring HLA-C and distinct from corneodesmosin and HCR</article-title>
          <source>Hum Genet</source>
          <year>2005</year>
          <volume>118</volume>
          <fpage>466</fpage>
          <lpage>476</lpage>
          <pub-id pub-id-type="doi">10.1007/s00439-005-0048-2</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Helms C, Saccone NL, Cao L et al (2005) Localization of PSORS1 to a haplotype block harbouring HLA-C and distinct from corneodesmosin and HCR. Hum Genet 118:466&#x2013;476 <pub-id pub-id-type="pmid">16235096</pub-id></citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Henseler</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Christophers</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Disease concomitance in psoriasis</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1995</year>
          <volume>32</volume>
          <fpage>982</fpage>
          <lpage>986</lpage>
          <pub-id pub-id-type="doi">10.1016/0190-9622(95)91336-X</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Henseler T, Christophers E (1995) Disease concomitance in psoriasis. J Am Acad Dermatol 32:982&#x2013;986 <pub-id pub-id-type="pmid">7751469</pub-id></citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Herron</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Hinckley</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hoffman</surname>
              <given-names>MS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Impact of obesity and smoking on psoriasis presentation and management</article-title>
          <source>Arch Dermatol</source>
          <year>2005</year>
          <volume>141</volume>
          <fpage>1527</fpage>
          <lpage>1534</lpage>
          <pub-id pub-id-type="doi">10.1001/archderm.141.12.1527</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Herron MD, Hinckley M, Hoffman MS et al (2005) Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 141:1527&#x2013;1534 <pub-id pub-id-type="pmid">16365253</pub-id></citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hurlimann</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Forster</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Noll</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis</article-title>
          <source>Circulation</source>
          <year>2002</year>
          <volume>106</volume>
          <fpage>2184</fpage>
          <lpage>2187</lpage>
          <pub-id pub-id-type="doi">10.1161/01.CIR.0000037521.71373.44</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Hurlimann D, Forster A, Noll G et al (2002) Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106:2184&#x2013;2187 <pub-id pub-id-type="pmid">12390945</pub-id></citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jacobsson</surname>
              <given-names>LTH</given-names>
            </name>
            <name>
              <surname>Turesson</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gulfe</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis</article-title>
          <source>J Rheumatol</source>
          <year>2005</year>
          <volume>32</volume>
          <fpage>1213</fpage>
          <lpage>1218</lpage>
        </citation>
        <citation citation-type="display-unstructured">Jacobsson LTH, Turesson C, Gulfe A et al (2005) Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 32:1213&#x2013;1218 <pub-id pub-id-type="pmid">15996054</pub-id></citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jones</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>CPD</given-names>
            </name>
            <name>
              <surname>Lloyd</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease</article-title>
          <source>Ann Rheum Dis</source>
          <year>2000</year>
          <volume>59</volume>
          <fpage>904</fpage>
          <lpage>909</lpage>
          <pub-id pub-id-type="doi">10.1136/ard.59.11.904</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Jones SM, Harris CPD, Lloyd J et al (2000) Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease. Ann Rheum Dis 59:904&#x2013;909 <pub-id pub-id-type="pmid">11053070</pub-id></citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaltwasser</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Nash</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gladman</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial</article-title>
          <source>Arthritis Rheum</source>
          <year>2004</year>
          <volume>50</volume>
          <fpage>1939</fpage>
          <lpage>1950</lpage>
          <pub-id pub-id-type="doi">10.1002/art.20253</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kaltwasser JP, Nash P, Gladman D et al (2004) Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50:1939&#x2013;1950 <pub-id pub-id-type="pmid">15188371</pub-id></citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaplan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>McCune</surname>
              <given-names>WJ</given-names>
            </name>
          </person-group>
          <article-title>New evidence for vascular disease in patients with early rheumatoid arthritis</article-title>
          <source>Lancet</source>
          <year>2003</year>
          <volume>361</volume>
          <fpage>1068</fpage>
          <lpage>1069</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(03)12901-7</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kaplan M, McCune WJ (2003) New evidence for vascular disease in patients with early rheumatoid arthritis. Lancet 361:1068&#x2013;1069 <pub-id pub-id-type="pmid">12672306</pub-id></citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kimball</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Jacobson</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The psychosocial burden of psoriasis</article-title>
          <source>Am J Clin Dermatol</source>
          <year>2005</year>
          <volume>6</volume>
          <fpage>383</fpage>
          <lpage>392</lpage>
          <pub-id pub-id-type="doi">10.2165/00128071-200506060-00005</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kimball AB, Jacobson C, Weiss S et al (2005) The psychosocial burden of psoriasis. Am J Clin Dermatol 6:383&#x2013;392 <pub-id pub-id-type="pmid">16343026</pub-id></citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kohler</surname>
              <given-names>GI</given-names>
            </name>
            <name>
              <surname>Bode-Boger</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Busse</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Drug&#x2013;drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use</article-title>
          <source>Int J Clin Pharmacol Ther</source>
          <year>2000</year>
          <volume>38</volume>
          <fpage>504</fpage>
          <lpage>513</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kohler GI, Bode-Boger SM, Busse R et al (2000) Drug&#x2013;drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 38:504&#x2013;513 <pub-id pub-id-type="pmid">11097142</pub-id></citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kruger-Krasagakis</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Galanopoulos</surname>
              <given-names>VK</given-names>
            </name>
            <name>
              <surname>Giannikaki</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Stefanidou</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tosca</surname>
              <given-names>AD</given-names>
            </name>
          </person-group>
          <article-title>Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis</article-title>
          <source>Br J Dermatol</source>
          <year>2006</year>
          <volume>154</volume>
          <fpage>460</fpage>
          <lpage>466</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2133.2005.07078.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kruger-Krasagakis S, Galanopoulos VK, Giannikaki L, Stefanidou M, Tosca AD (2006) Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis. Br J Dermatol 154:460&#x2013;466 <pub-id pub-id-type="pmid">16445776</pub-id></citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kuo</surname>
              <given-names>C-C</given-names>
            </name>
            <name>
              <surname>Campbell</surname>
              <given-names>LA</given-names>
            </name>
          </person-group>
          <article-title>Detection of <italic>Chlamydia pneumoniae</italic> in arterial tissues</article-title>
          <source>J Infec Dis</source>
          <year>2000</year>
          <volume>181</volume>
          <fpage>S432</fpage>
          <lpage>S436</lpage>
          <pub-id pub-id-type="doi">10.1086/315615</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kuo C-C, Campbell LA (2000) Detection of Chlamydia pneumoniae in arterial tissues. J Infec Dis 181:S432&#x2013;S436 <pub-id pub-id-type="pmid">10839731</pub-id></citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Bellary</surname>
              <given-names>SV</given-names>
            </name>
            <name>
              <surname>Francis</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Increased occurrence of psoriasis in patients with Crohn&#x2019;s disease and their relatives</article-title>
          <source>Am J Gastroenterol</source>
          <year>1990</year>
          <volume>85</volume>
          <fpage>962</fpage>
          <lpage>963</lpage>
        </citation>
        <citation citation-type="display-unstructured">Lee FJ, Bellary SV, Francis C (1990) Increased occurrence of psoriasis in patients with Crohn&#x2019;s disease and their relatives. Am J Gastroenterol 85:962&#x2013;963 <pub-id pub-id-type="pmid">2375323</pub-id></citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Libby</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ridker</surname>
              <given-names>PM</given-names>
            </name>
          </person-group>
          <article-title>Inflammation and atherosclerosis: role of C-reactive protein in risk assessment</article-title>
          <source>Am J Med</source>
          <year>2004</year>
          <volume>116</volume>
          <fpage>9S</fpage>
          <lpage>16S</lpage>
          <pub-id pub-id-type="doi">10.1016/j.amjmed.2004.02.006</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Libby P, Ridker PM (2004) Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 116:9S&#x2013;16S <pub-id pub-id-type="pmid">15050187</pub-id></citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lindegard</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes</article-title>
          <source>Dermatologica</source>
          <year>1986</year>
          <volume>172</volume>
          <fpage>298</fpage>
          <lpage>304</lpage>
        </citation>
        <citation citation-type="display-unstructured">Lindegard B (1986) Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 172:298&#x2013;304 <pub-id pub-id-type="pmid">3089849</pub-id></citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lundberg</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Johannesson</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Silverdahl</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity</article-title>
          <source>Acta Derm Venereol</source>
          <year>2000</year>
          <volume>80</volume>
          <fpage>430</fpage>
          <lpage>434</lpage>
          <pub-id pub-id-type="doi">10.1080/000155500300012873</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Lundberg L, Johannesson M, Silverdahl M et al (2000) Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol 80:430&#x2013;434 <pub-id pub-id-type="pmid">11243637</pub-id></citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Madland</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Apalset</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Johannessen</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Rossebo</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Brun</surname>
              <given-names>JG</given-names>
            </name>
          </person-group>
          <article-title>Prevalence, disease manifestations, and treatment of psoriatic arthritis in Western Norway</article-title>
          <source>J Rheumatol</source>
          <year>2005</year>
          <volume>32</volume>
          <fpage>1918</fpage>
          <lpage>1922</lpage>
        </citation>
        <citation citation-type="display-unstructured">Madland TM, Apalset EM, Johannessen AE, Rossebo B, Brun JG (2005) Prevalence, disease manifestations, and treatment of psoriatic arthritis in Western Norway. J Rheumatol 32:1918&#x2013;1922 <pub-id pub-id-type="pmid">16206347</pub-id></citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mallbris</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Akre</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Granath</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients</article-title>
          <source>Eur J Epidemiol</source>
          <year>2004</year>
          <volume>19</volume>
          <fpage>225</fpage>
          <lpage>230</lpage>
          <pub-id pub-id-type="doi">10.1023/B:EJEP.0000020447.59150.f9</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Mallbris L, Akre O, Granath F et al (2004) Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 19:225&#x2013;230 <pub-id pub-id-type="pmid">15117115</pub-id></citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McCarey</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>McInnes</surname>
              <given-names>IB</given-names>
            </name>
            <name>
              <surname>Madhok</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial</article-title>
          <source>Lancet</source>
          <year>2004</year>
          <volume>363</volume>
          <fpage>2015</fpage>
          <lpage>2021</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(04)16449-0</pub-id>
        </citation>
        <citation citation-type="display-unstructured">McCarey DW, McInnes IB, Madhok R et al (2004) Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363:2015&#x2013;2021 <pub-id pub-id-type="pmid">15207950</pub-id></citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McDonald</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Calabresi</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Psoriasis and occlusive vascular disease</article-title>
          <source>Br J Dermatol</source>
          <year>1978</year>
          <volume>99</volume>
          <fpage>469</fpage>
          <lpage>475</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2133.1978.tb02012.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">McDonald CJ, Calabresi P (1978) Psoriasis and occlusive vascular disease. Br J Dermatol 99:469&#x2013;475 <pub-id pub-id-type="pmid">708620</pub-id></citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mease</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Kivitz</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Burch</surname>
              <given-names>FX</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression</article-title>
          <source>Arthritis Rheum</source>
          <year>2004</year>
          <volume>50</volume>
          <fpage>2264</fpage>
          <lpage>2272</lpage>
          <pub-id pub-id-type="doi">10.1002/art.20335</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Mease PJ, Kivitz AJ, Burch FX et al (2004) Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50:2264&#x2013;2272 <pub-id pub-id-type="pmid">15248226</pub-id></citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morse</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Perry</surname>
              <given-names>HO</given-names>
            </name>
            <name>
              <surname>Hurt</surname>
              <given-names>RD</given-names>
            </name>
          </person-group>
          <article-title>Alcoholism and psoriasis</article-title>
          <source>Alcohol Clin Exp Res</source>
          <year>1985</year>
          <volume>9</volume>
          <fpage>396</fpage>
          <lpage>399</lpage>
        </citation>
        <citation citation-type="display-unstructured">Morse RM, Perry HO, Hurt RD (1985) Alcoholism and psoriasis. Alcohol Clin Exp Res 9:396&#x2013;399 <pub-id pub-id-type="pmid">3904504</pub-id></citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nair</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Stuart</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Nistor</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene</article-title>
          <source>Am J Hum Genet</source>
          <year>2006</year>
          <volume>78</volume>
          <fpage>827</fpage>
          <lpage>851</lpage>
          <pub-id pub-id-type="doi">10.1086/503821</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Nair RP, Stuart PE, Nistor I et al (2006) Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 78:827&#x2013;851 <pub-id pub-id-type="pmid">16642438</pub-id></citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Naldi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Chatenoud</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Linder</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study</article-title>
          <source>J Invest Dermatol</source>
          <year>2005</year>
          <volume>125</volume>
          <fpage>61</fpage>
          <lpage>67</lpage>
          <pub-id pub-id-type="doi">10.1111/j.0022-202X.2005.23681.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Naldi L, Chatenoud L, Linder D et al (2005) Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 125:61&#x2013;67 <pub-id pub-id-type="pmid">15982303</pub-id></citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Namazi</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>Statins: novel additions to the dermatologic arsenal?</article-title>
          <source>Exp Dermatol</source>
          <year>2004</year>
          <volume>13</volume>
          <fpage>337</fpage>
          <lpage>339</lpage>
          <pub-id pub-id-type="doi">10.1111/j.0906-6705.2004.00208.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Namazi MR (2004) Statins: novel additions to the dermatologic arsenal? Exp Dermatol 13:337&#x2013;339 <pub-id pub-id-type="pmid">15186318</pub-id></citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nash</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Clegg</surname>
              <given-names>DO</given-names>
            </name>
          </person-group>
          <article-title>Psoriatic arthritis therapy: NSAIDs and traditional DMARDs</article-title>
          <source>Ann Rheum Dis</source>
          <year>2005</year>
          <volume>64</volume>
          <fpage>ii74</fpage>
          <lpage>ii77</lpage>
          <pub-id pub-id-type="doi">10.1136/ard.2004.030783</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Nash P, Clegg DO (2005) Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 64:ii74&#x2013;ii77 <pub-id pub-id-type="pmid">15708943</pub-id></citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nickoloff</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Nestle</surname>
              <given-names>FO</given-names>
            </name>
          </person-group>
          <article-title>Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities</article-title>
          <source>J Clin Invest</source>
          <year>2004</year>
          <volume>113</volume>
          <fpage>1664</fpage>
          <lpage>1675</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI200422147</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Nickoloff BJ, Nestle FO (2004) Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 113:1664&#x2013;1675 <pub-id pub-id-type="pmid">15199399</pub-id></citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oh</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Arkfeld</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Horwitz</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Development of Crohn&#x2019;s disease in a patient taking etanercept</article-title>
          <source>J Rheumatol</source>
          <year>2005</year>
          <volume>32</volume>
          <fpage>752</fpage>
          <lpage>753</lpage>
        </citation>
        <citation citation-type="display-unstructured">Oh J, Arkfeld DG, Horwitz DA (2005) Development of Crohn&#x2019;s disease in a patient taking etanercept. J Rheumatol 32:752&#x2013;753 <pub-id pub-id-type="pmid">15801037</pub-id></citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pearce</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Morrison</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Higgins</surname>
              <given-names>KB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The comorbid state of psoriasis patients in a university dermatology practice</article-title>
          <source>J Derm Treat</source>
          <year>2005</year>
          <volume>16</volume>
          <fpage>319</fpage>
          <lpage>323</lpage>
          <pub-id pub-id-type="doi">10.1080/09546630500335977</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Pearce DJ, Morrison AE, Higgins KB et al (2005) The comorbid state of psoriasis patients in a university dermatology practice. J Derm Treat 16:319&#x2013;323 </citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Persson</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Leijonmarck</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Bernell</surname>
              <given-names>O</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Risk indicators for inflammatory bowel disease</article-title>
          <source>Int J Epidemiol</source>
          <year>1993</year>
          <volume>22</volume>
          <fpage>268</fpage>
          <lpage>272</lpage>
        </citation>
        <citation citation-type="display-unstructured">Persson PG, Leijonmarck CE, Bernell O et al (1993) Risk indicators for inflammatory bowel disease. Int J Epidemiol 22:268&#x2013;272 <pub-id pub-id-type="pmid">8505183</pub-id></citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peters</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Horst-Bruinsma</surname>
              <given-names>IE</given-names>
            </name>
            <name>
              <surname>Dijkmans</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Nurmohamed</surname>
              <given-names>MT</given-names>
            </name>
          </person-group>
          <article-title>Cardiovascular risk profile of patients with spondyloarthropathies, particularly ankylosing spondylitis and psoriatic arthritis</article-title>
          <source>Semin Arthritis Rheum</source>
          <year>2004</year>
          <volume>34</volume>
          <fpage>585</fpage>
          <lpage>592</lpage>
          <pub-id pub-id-type="doi">10.1016/j.semarthrit.2004.07.010</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT (2004) Cardiovascular risk profile of patients with spondyloarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34:585&#x2013;592 <pub-id pub-id-type="pmid">15609262</pub-id></citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Poikolainen</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Karvonen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pukkal</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis</article-title>
          <source>Arch Dermatol</source>
          <year>1999</year>
          <volume>135</volume>
          <fpage>1490</fpage>
          <lpage>1493</lpage>
          <pub-id pub-id-type="doi">10.1001/archderm.135.12.1490</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Poikolainen K, Karvonen J, Pukkal E (1999) Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol 135:1490&#x2013;1493 <pub-id pub-id-type="pmid">10606054</pub-id></citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Prodanowich</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>JR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2005</year>
          <volume>52</volume>
          <fpage>262</fpage>
          <lpage>267</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jaad.2004.06.017</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Prodanowich S, Ma F, Taylor JR et al (2005) Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 52:262&#x2013;267 <pub-id pub-id-type="pmid">15692471</pub-id></citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rahman</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Elder</surname>
              <given-names>JT</given-names>
            </name>
          </person-group>
          <article-title>Genetic epidemiology of psoriasis and psoriatic arthritis</article-title>
          <source>Ann Rheum Dis</source>
          <year>2005</year>
          <volume>64</volume>
          <fpage>ii37</fpage>
          <lpage>ii39</lpage>
          <pub-id pub-id-type="doi">10.1136/ard.2004.030775</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Rahman P, Elder JT (2005) Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 64:ii37&#x2013;ii39 <pub-id pub-id-type="pmid">15708933</pub-id></citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rapp</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Exum</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Fleischer</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Beboussin</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>Psoriasis causes as much disability as other major medical diseases</article-title>
          <source>J Am Acad Dermatol</source>
          <year>1999</year>
          <volume>41</volume>
          <issue>3 Pt 1</issue>
          <fpage>401</fpage>
          <lpage>407</lpage>
          <pub-id pub-id-type="doi">10.1016/S0190-9622(99)70112-X</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Beboussin DM (1999) Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41(3 Pt 1):401&#x2013;407 <pub-id pub-id-type="pmid">10459113</pub-id></citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reynoso-von Drateln</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Martinez-Abundis</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Balcazar-Munoz</surname>
              <given-names>BR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Lipid profile, insulin secretion, and insulin sensitivity in psoriasis</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2003</year>
          <volume>48</volume>
          <fpage>882</fpage>
          <lpage>885</lpage>
          <pub-id pub-id-type="doi">10.1067/mjd.2003.446</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Reynoso-von Drateln C, Martinez-Abundis E, Balcazar-Munoz BR et al (2003) Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol 48:882&#x2013;885 <pub-id pub-id-type="pmid">12789179</pub-id></citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rispo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Scarpa</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Di Girolamo</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Infliximab in the treatment of extra-intestinal manifestations of Crohn&#x2019;s disease</article-title>
          <source>Scand J Rheumatol</source>
          <year>2005</year>
          <volume>34</volume>
          <fpage>387</fpage>
          <lpage>391</lpage>
          <pub-id pub-id-type="doi">10.1080/03009740510026698</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Rispo A, Scarpa R, Di Girolamo E et al (2005) Infliximab in the treatment of extra-intestinal manifestations of Crohn&#x2019;s disease. Scand J Rheumatol 34:387&#x2013;391 <pub-id pub-id-type="pmid">16234187</pub-id></citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rocha-Pereira</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Santos-Silva</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rebelo</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease</article-title>
          <source>Clin Chim Acta</source>
          <year>2001</year>
          <volume>303</volume>
          <fpage>33</fpage>
          <lpage>39</lpage>
          <pub-id pub-id-type="doi">10.1016/S0009-8981(00)00358-2</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Rocha-Pereira P, Santos-Silva A, Rebelo I, et al (2001) Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 303:33&#x2013;39 <pub-id pub-id-type="pmid">11163020</pub-id></citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Saikku</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Leinonen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mattila</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction</article-title>
          <source>Lancet</source>
          <year>1988</year>
          <volume>2</volume>
          <fpage>983</fpage>
          <lpage>986</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(88)90741-6</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Saikku P, Leinonen M, Mattila K et al (1988) Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 2:983&#x2013;986 <pub-id pub-id-type="pmid">2902492</pub-id></citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sattar</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>McInnes</surname>
              <given-names>IB</given-names>
            </name>
          </person-group>
          <article-title>Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions</article-title>
          <source>Curr Opin Rheumatol</source>
          <year>2005</year>
          <volume>17</volume>
          <fpage>286</fpage>
          <lpage>292</lpage>
          <pub-id pub-id-type="doi">10.1097/01.bor.0000158150.57154.f9</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Sattar N, McInnes IB (2005) Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol 17:286&#x2013;292 <pub-id pub-id-type="pmid">15838238</pub-id></citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schmitt</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Carstensen</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bugdahl</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Christophers</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Weichenthal</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>The association of psoriasis vulgaris with internal diseases</article-title>
          <source>Arch Dermatol Res</source>
          <year>2003</year>
          <volume>294</volume>
          <fpage>487</fpage>
        </citation>
        <citation citation-type="display-unstructured">Schmitt D, Carstensen K, Bugdahl R, Christophers E, Weichenthal M (2003) The association of psoriasis vulgaris with internal diseases. Arch Dermatol Res 294:487 </citation>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schroder</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Low dose methotrexate in inflammatory bowel disease: current status and future directions</article-title>
          <source>Am J Gastroenterol</source>
          <year>2003</year>
          <volume>98</volume>
          <fpage>530</fpage>
          <lpage>537</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1572-0241.2003.07305.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Schroder O, Stein J (2003) Low dose methotrexate in inflammatory bowel disease: current status and future directions. Am J Gastroenterol 98:530&#x2013;537 <pub-id pub-id-type="pmid">12650783</pub-id></citation>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stern</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Kleinerman</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Parrish</surname>
              <given-names>JA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Phototoxic reactions to photoactive drugs in patients treated with PUVA</article-title>
          <source>Arch Dermatol</source>
          <year>1980</year>
          <volume>116</volume>
          <fpage>1269</fpage>
          <lpage>1271</lpage>
          <pub-id pub-id-type="doi">10.1001/archderm.116.11.1269</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Stern RS, Kleinerman RA, Parrish JA et al (1980) Phototoxic reactions to photoactive drugs in patients treated with PUVA. Arch Dermatol 116:1269&#x2013;1271 <pub-id pub-id-type="pmid">6776898</pub-id></citation>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Strong</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mathers</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Leeder</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Beaglehole</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Preventing chronic diseases: how many lives can we save?</article-title>
          <source>Lancet</source>
          <year>2005</year>
          <volume>366</volume>
          <fpage>1578</fpage>
          <lpage>1582</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(05)67341-2</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Strong K, Mathers C, Leeder S, Beaglehole R (2005) Preventing chronic diseases: how many lives can we save? Lancet 366:1578&#x2013;1582 <pub-id pub-id-type="pmid">16257345</pub-id></citation>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Swanbeck</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Inerot</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Martinsson</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wahlstrom</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>A population genetic study of psoriasis</article-title>
          <source>Br J Dermatol</source>
          <year>1994</year>
          <volume>131</volume>
          <fpage>32</fpage>
          <lpage>39</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2133.1994.tb08454.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Swanbeck G, Inerot A, Martinsson T, Wahlstrom J (1994) A population genetic study of psoriasis. Br J Dermatol 131:32&#x2013;39 <pub-id pub-id-type="pmid">8043420</pub-id></citation>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Swanbeck</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Inerot</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Martinsson</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genetic counselling in psoriasis: empirical data on psoriasis among first-degree relatives of 3095 psoriatic probands</article-title>
          <source>Br J Dermatol</source>
          <year>1997</year>
          <volume>137</volume>
          <fpage>939</fpage>
          <lpage>942</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2133.1997.19892070.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Swanbeck G, Inerot A, Martinsson T et al (1997) Genetic counselling in psoriasis: empirical data on psoriasis among first-degree relatives of 3095 psoriatic probands. Br J Dermatol 137:939&#x2013;942 <pub-id pub-id-type="pmid">9470911</pub-id></citation>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tikiz</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Utuk</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Pirildar</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effects of angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis</article-title>
          <source>J Rheumatol</source>
          <year>2005</year>
          <volume>32</volume>
          <fpage>2095</fpage>
          <lpage>2101</lpage>
        </citation>
        <citation citation-type="display-unstructured">Tikiz C, Utuk O, Pirildar T et al (2005) Effects of angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. J Rheumatol 32:2095&#x2013;2101 <pub-id pub-id-type="pmid">16265685</pub-id></citation>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsankov</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Angelova</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Kazandjieva</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Drug-induced psoriasis. Recognition and management</article-title>
          <source>Am J Clin Dermatol</source>
          <year>2000</year>
          <volume>1</volume>
          <fpage>159</fpage>
          <lpage>165</lpage>
          <pub-id pub-id-type="doi">10.2165/00128071-200001030-00003</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Tsankov N, Angelova I, Kazandjieva J (2000) Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol 1:159&#x2013;165 <pub-id pub-id-type="pmid">11702297</pub-id></citation>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Uyanik</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Ari</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Onur</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Serum lipids and apolipoproteins in patients psoriasis</article-title>
          <source>Clin Chem Lab Med</source>
          <year>2002</year>
          <volume>40</volume>
          <fpage>65</fpage>
          <lpage>68</lpage>
          <pub-id pub-id-type="doi">10.1515/CCLM.2002.013</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Uyanik BS, Ari Z, Onur E et al (2002) Serum lipids and apolipoproteins in patients psoriasis. Clin Chem Lab Med 40:65&#x2013;68 <pub-id pub-id-type="pmid">11916273</pub-id></citation>
      </ref>
      <ref id="CR74">
        <label>74.</label>
        <citation citation-type="other">Van de Kerkhof P et al. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.psori.fi/doc/patient_survey_2nd_phase(2003.pdf">http://www.psori.fi/doc/patient_survey_2nd_phase(2003).pdf</ext-link>. Accessed September 15, 2005</citation>
      </ref>
      <ref id="CR75">
        <label>75.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Doornum</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>McColl</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Wicks</surname>
              <given-names>IP</given-names>
            </name>
          </person-group>
          <article-title>Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?</article-title>
          <source>Arthritis Rheum</source>
          <year>2002</year>
          <volume>46</volume>
          <fpage>862</fpage>
          <lpage>873</lpage>
          <pub-id pub-id-type="doi">10.1002/art.10089</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Van Doornum S, McColl G, Wicks IP (2002) Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 46:862&#x2013;873 <pub-id pub-id-type="pmid">11953961</pub-id></citation>
      </ref>
      <ref id="CR76">
        <label>76.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vasku</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Kankova</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Vasku</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Gene polymorphisms (G82S, 1704G/T, 2184A/G and 2245G/A) of the receptor of advanced glycation end products (RAGE) in plaque psoriasis</article-title>
          <source>Arch Dermatol Res</source>
          <year>2002</year>
          <volume>294</volume>
          <fpage>127</fpage>
          <lpage>1230</lpage>
          <pub-id pub-id-type="doi">10.1007/s00403-002-0301-7</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Vasku V, Kankova K, Vasku A et al (2002) Gene polymorphisms (G82S, 1704G/T, 2184A/G and 2245G/A) of the receptor of advanced glycation end products (RAGE) in plaque psoriasis. Arch Dermatol Res 294:127&#x2013;1230 <pub-id pub-id-type="pmid">12029499</pub-id></citation>
      </ref>
      <ref id="CR77">
        <label>77.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Veal</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Capon</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Allen</surname>
              <given-names>MH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psorisasis-susceptibility locus</article-title>
          <source>Am J Hum Genet</source>
          <year>2002</year>
          <volume>71</volume>
          <fpage>554</fpage>
          <lpage>564</lpage>
          <pub-id pub-id-type="doi">10.1086/342289</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Veal CD, Capon F, Allen MH et al (2002) Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psorisasis-susceptibility locus. Am J Hum Genet 71:554&#x2013;564 <pub-id pub-id-type="pmid">12148091</pub-id></citation>
      </ref>
      <ref id="CR78">
        <label>78.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wallberg-Jonsson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cvetkovic</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Sundqvist</surname>
              <given-names>K-G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis</article-title>
          <source>J Rheumatol</source>
          <year>2002</year>
          <volume>29</volume>
          <fpage>875</fpage>
          <lpage>882</lpage>
        </citation>
        <citation citation-type="display-unstructured">Wallberg-Jonsson S, Cvetkovic JT, Sundqvist K-G et al (2002) Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 29:875&#x2013;882 <pub-id pub-id-type="pmid">12022343</pub-id></citation>
      </ref>
      <ref id="CR79">
        <label>79.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Williams</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Meyers</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Immune-mediated inflammatory disorders (I.M.I.D.s): the economic and clinical costs</article-title>
          <source>Am J Manag Care</source>
          <year>2002</year>
          <volume>8</volume>
          <fpage>S664</fpage>
          <lpage>S681</lpage>
        </citation>
        <citation citation-type="display-unstructured">Williams JP, Meyers JA (2002) Immune-mediated inflammatory disorders (I.M.I.D.s): the economic and clinical costs. Am J Manag Care 8:S664&#x2013;S681 <pub-id pub-id-type="pmid">12516953</pub-id></citation>
      </ref>
      <ref id="CR80">
        <label>80.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wong</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Gladman</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Husted</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death</article-title>
          <source>Arthritis Rheum</source>
          <year>1997</year>
          <volume>40</volume>
          <fpage>1868</fpage>
          <lpage>1872</lpage>
        </citation>
        <citation citation-type="display-unstructured">Wong K, Gladman DD, Husted J et al (1997) Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 40:1868&#x2013;1872 <pub-id pub-id-type="pmid">9336423</pub-id></citation>
      </ref>
      <ref id="CR81">
        <label>81.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xiao</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Xiao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Serum apolipoprotein levels of psoriatic patients with normal serum lipid levels</article-title>
          <source>Chin Med Sci J</source>
          <year>1997</year>
          <volume>12</volume>
          <fpage>224</fpage>
          <lpage>228</lpage>
        </citation>
        <citation citation-type="display-unstructured">Xiao T, Yang C, Xiao Y, Song F (1997) Serum apolipoprotein levels of psoriatic patients with normal serum lipid levels. Chin Med Sci J 12:224&#x2013;228 <pub-id pub-id-type="pmid">11360555</pub-id></citation>
      </ref>
      <ref id="CR82">
        <label>82.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yates</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Watkinson</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kelman</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Further evidence for an association between psoriasis, Crohn&#x2019;s disease and ulcerative colitis</article-title>
          <source>Br J Dermatol</source>
          <year>1982</year>
          <volume>106</volume>
          <fpage>323</fpage>
          <lpage>330</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2133.1982.tb01731.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Yates VM, Watkinson G, Kelman A (1982) Further evidence for an association between psoriasis, Crohn&#x2019;s disease and ulcerative colitis. Br J Dermatol 106:323&#x2013;330 <pub-id pub-id-type="pmid">7066192</pub-id></citation>
      </ref>
      <ref id="CR83">
        <label>83.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zachariae</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Zachariae</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Blomqvist</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study</article-title>
          <source>Acta Derm Venereol</source>
          <year>2002</year>
          <volume>82</volume>
          <fpage>108</fpage>
          <lpage>113</lpage>
          <pub-id pub-id-type="doi">10.1080/00015550252948130</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Zachariae H, Zachariae R, Blomqvist K et al (2002) Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol 82:108&#x2013;113 <pub-id pub-id-type="pmid">12125937</pub-id></citation>
      </ref>
      <ref id="CR84">
        <label>84.</label>
        <citation citation-type="other">Zahl V, Gerdes S, Mrowietz U Co-medication in patients with severe psoriasis: first results of a retrospective analysis in 1203 hospitalized patients in Germany. Presented at the 4th International Congress&#x2014;The Royal College of Physicians, December 1&#x2013;3, 2005, London, P-67</citation>
      </ref>
      <ref id="CR85">
        <label>85.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zevin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Benowitz</surname>
              <given-names>NL</given-names>
            </name>
          </person-group>
          <article-title>Drug interactions with tobacco smoking. An update</article-title>
          <source>Clin Pharmacokinet</source>
          <year>1999</year>
          <volume>36</volume>
          <fpage>425</fpage>
          <lpage>438</lpage>
          <pub-id pub-id-type="doi">10.2165/00003088-199936060-00004</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Zevin S, Benowitz NL (1999) Drug interactions with tobacco smoking. An update. Clin Pharmacokinet 36:425&#x2013;438 <pub-id pub-id-type="pmid">10427467</pub-id></citation>
      </ref>
      <ref id="CR86">
        <label>86.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zimmet</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Maglano</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Matsuzawa</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The metabolic syndrome: a global public health problem and a new definition</article-title>
          <source>J Atheroscler Thromb</source>
          <year>2005</year>
          <volume>12</volume>
          <fpage>295</fpage>
          <lpage>300</lpage>
        </citation>
        <citation citation-type="display-unstructured">Zimmet P, Maglano D, Matsuzawa Y et al (2005) The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 12:295&#x2013;300 <pub-id pub-id-type="pmid">16394610</pub-id></citation>
      </ref>
    </ref-list>
    <fn-group>
      <fn>
        <p>The authors are consultants to Schering-Plough Pharmaceuticals and have received an honorarium for their participation in this programme.</p>
      </fn>
    </fn-group>
  </back>
</article>
</pmc-articleset>